News


  • 01 February 2018

    Celtaxsys announces the issue of four new patents expanding its pipeline of selective leukotriene B4 modulation anti-inflammatory medicines

    Celtaxsys announces the issue of four new patents expanding its pipeline of selective leukotriene B4 modulation anti-inflammatory medicines

    Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare inflammatory diseases, announced today the issuance of four new patents, extending its leadership position in development of a robust pipeline of inhibitors of Leukotriene A4 Hydrolase (LTA4H), the key rate limiting enzyme in production of the inflammatory mediator Leukotriene B4 (LTB4).  LTB4 is a potent mediator of neutrophil activity and when over-expressed, can lead to hyper-activation of neutrophils, resulting in sustained inflammation, tissue damage and reduced organ function, including in the lungs of CF patients. 

  • 01 February 2018

    Syndax Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca

    Syndax Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca

    Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced a new clinical collaboration with AstraZeneca  to evaluate the safety and efficacy of AstraZeneca's durvalumab, a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1), in combination with SNDX-6352, Syndax's monoclonal antibody inhibitor of Colony-Stimulating Factor 1 Receptor (CSF1R), across a variety of solid tumors.

  • 25 January 2018

    Evofem Biosciences Announces First Patient Enrolled in Phase 2b/3 STI Trial of Amphora® and Expects Phase 3 Contraceptive Clinical Trial Data First Quarter 2019

    Evofem Biosciences Announces First Patient Enrolled in Phase 2b/3 STI Trial of Amphora® and Expects Phase 3 Contraceptive Clinical Trial Data First Quarter 2019

    Evofem Biosciences, Inc., (NASDAQ: EVFM), a clinical-stage specialty biopharmaceutical company focused on the development and commercialization of women's healthcare products, today announced enrollment of the first patient in a Phase 2b/3 clinical trial evaluating Amphora and its ability to prevent urogenital chlamydia and gonorrhea in women.  Amphora is an investigational compound being studied for the prevention of certain reproductive tract infections and as an on-demand, non-hormonal vaginal contraceptive.

  • 18 January 2018

    Evofem Announces Closing Of Merger With Neothetics

    Evofem Announces Closing Of Merger With Neothetics

    Evofem Biosciences, Inc. (NASDAQ: EVFM), today announced the closing of the previously announced merger with Neothetics, Inc. (NASDAQ: NEOT).  The merged company will operate as Evofem Biosciences, Inc. and will focus on the continued development and commercialization of women's healthcare products. 

  • 10 January 2018

    Syndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer

    Syndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer

    Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced a new clinical collaboration with  Genentech , a member of the Roche Group. As part of the collaboration, the two companies will evaluate the combination of Syndax's entinostat, an oral, small molecule, class I HDAC inhibitor, and  Genentech's  programmed cell death ligand 1 (PD-L1) blocking antibody, atezolizumab (TECENTRIQ®), in patients with second-line hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+, HER2-) metastatic breast cancer.

  • 05 January 2018

    Life Sciences Pioneer Stanley Lapidus Joins Atlas Genetics Board of Director

    Life Sciences Pioneer Stanley Lapidus Joins Atlas Genetics Board of Director

    Atlas Genetics, a rapid, near-patient and point-of-care (POC) testing company, today announced that it has appointed Stanley Lapidus to the role of independent board member on its Board of Directors. Lapidus has more than 30 years’ experience in the medical diagnostics industry as a founder, CEO and board member at companies that have dramatically impacted the diagnostics landscape, including his founding of EXACT Sciences Corp. (NASDAQ:EXAS) and, prior to that, Cytyc Corp., which was sold to Hologic Corporation in 2007.

  • 04 January 2018

    Epic Sciences To Present At The 2nd Annual CTIC Capital Cross-Border China-US Healthcare Investment Summit

    Epic Sciences To Present At The 2nd Annual CTIC Capital Cross-Border China-US Healthcare Investment Summit

    Epic Sciences, Inc. (Epic) announces that it is one of six companies chosen to present at the second annual CTIC Capital Cross-Border China-US Healthcare Investment Summit. The summit will take place on Sunday, January 7 at the Hyatt Regency in San Francisco. 

  • 04 January 2018

    Celtaxsys Secures Private Financing to Advance Acebilustat Phase 3 Cystic Fibrosis (CF) Program Preparatory Activities

    Celtaxsys Secures Private Financing to Advance Acebilustat Phase 3 Cystic Fibrosis (CF) Program Preparatory Activities

    Celtaxsys, Inc., a clinical stage drug development company focused on developing novel therapies for rare inflammatory diseases, today announced the successful completion of a Series E financing led by Invus. Additional investors in the financing include Domain Associates, Lumira Capital, Masters Capital Management, RMI Partners and the Georgia Research Alliance Venture Fund.  In conjunction with the financing, Khalil Barrage, Managing Director at Invus, will join Celtaxsys’ board of directors.

  • 27 December 2017

    Happy New Year!

    Happy New Year!

    Wish you a peaceful and heartwarming Holiday Season, and the New Year ahead!

  • 13 December 2017

    Marinus Pharmaceuticals Added to NASDAQ Biotechnology Index

    Marinus Pharmaceuticals Added to NASDAQ Biotechnology Index

    Marinus Pharmaceuticals, Inc.(Nasdaq:MRNS) (the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that it has been selected for addition to the NASDAQ Biotechnology Index®, which will become effective prior to the open of U.S. markets Monday, December 18, 2017.